logo
Plus   Neg
Share
Email

Soligenix Inc. (SNGX) Is Surging After Orphan Drug Designation

Soligenix Inc. (SNGX) announced Thursday morning that it has been granted an orphan drug designation for RiVax from the European Commission. RiVax is a drug for the prevention of ricin poisoning.

Soligenix gapped up slightly Thursday and has spiked higher in early trade. The stock is now up 0.93 at $2.93 on above average volume. Soligenix has surged to an 8-month high.

by RTTNews Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Follow RTT